Abstract

Research Article

Cognition and Memory Impairment among Patients of Depression in Pakistan-The Role of Conventional and Newer Anti-Depressants

Madeeha Malik*, Muhammad Usama Khan, Azhar Hussain and Ayisha Hashmi

Published: 17 July, 2019 | Volume 3 - Issue 1 | Pages: 020-024

Background: Antidepressant therapy is the most adopted treatment option for depression. The evaluation of cognitive effects related to antidepressant drug use is important for better selection of antidepressant drugs that leads to improved cognitive performance and patient health related quality of life. Aim: The aim of the present study was to evaluate the effects of antidepressant drugs on cognition and memory among patients of depression in Pakistan.

Method: A descriptive cross-sectional study design was used. A pre-validated data collection tool Mini Mental State Examination was used. The sample size was calculated to be 382 with 95% confidence interval and 5% level of error. The data was cleaned, coded and analyzed statistically using spss 21. Chi-Square test (p ≥ 0.05) was used to find association among different variables.

Results: The results showed that out of 382 respondents, 7.3% (n=28) were being prescribed amytryptyline and among them 46% (n=13) had questionably significant cognitive impairment and 53% (n=15) had mild cognitive impairment. On the other hand out of 23% (n=89) patients on escitalopram monotherapy, 85% (n=76) had impairment of questionably significant impairment and only 13.4% (n=12) had mild impairment. Area of residence and medication therapy were significant variables (p<0.05) that can affect cognition and memory among patients of depression.

Conclusion: The results of present study concluded cognitive impairment of questionably significant nature among patients of depression in Pakistan. For the better management of depression, it is recommended that anti-depressant drug therapy should be tailored according to individual patient requirements. 

Read Full Article HTML DOI: 10.29328/journal.apmh.1001006 Cite this Article Read Full Article PDF

References

  1. Reporters. 34 per cent Pakistanis suffer from depression. The Nation. 2012.
  2. Organization WH. WHO Depression Fact Sheet (updated February 2017). 2017.
  3. Duthey B. Priority medicines for europe and the world:“a public health approach to innovation”. WHO Background paper. 2013; 6.
  4. Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry research. 2014; 220: 245-50. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25124683
  5. Reddy S, Fayyad R, Edgar CJ, Guico-Pabia CJ, Wesnes K. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology. 2016; 30: 559-67. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27009044
  6. Koenig HG, Al Zaben F, Sehlo MG, Khalifa DA, Al Ahwal MS. et al. Mental health care in Saudi Arabia: Past, present and future. Open Journal of Psychiatry. 2014; 4: 113.
  7. Noh S, Kaspar V. Perceived discrimination and depression: Moderating effects of coping, acculturation, and ethnic support. American journal of public health. 2003; 93: 232-8. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447722/
  8. Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychological medicine. 2004; 34: 83-91. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14971629
  9. Kessler RC. Epidemiology of women and depression. Journal of affective disorders. 2003; 74: 5-13. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12646294
  10. Ganatra HA, Zafar SN, Qidwai W, Rozi S. Prevalence and predictors of depression among an elderly population of Pakistan. Aging and Mental Health. 2008; 12: 349-56. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18728948
  11. Everson SA, Maty SC, Lynch JW, Kaplan GA. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. Journal of psychosomatic research. 2002;53(4):891-5.PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12377299
  12. Patel V, Rodrigues M, DeSouza N. Gender, poverty, and postnatal depression: a study of mothers in Goa, India. American journal of Psychiatry. 2002; 159: 43-7. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11772688
  13. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. International Journal of Neuropsychopharmacology. 2016; 19. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26209859
  14. Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depression research and treatment. 2014; 2014.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More